A phase I study of the novel molecularly targeted vascular targeting agent, Exherin (ADH-1), shows activity in some patients with refractory solid tumors stratified according to N-cadherin expression

Derek J. Jonker, W. P. Peters, Rakesh Goel et al.|Journal of Clinical Oncology|2005

Cited by 6